Get started
MediWound Ltd.MediWound Ltd.MediWound Ltd.

MediWound Ltd.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

MDWD trade ideas

$MDWD is gonna fall todayPupm&Dump trading strategy idea. $MDWD is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $5,52; stop-loss — $5,97; take-profit — $4,62. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:MDWDShort
by KozakHlib
Innovation Product Launch For MDWD Sparks Bullish MoveCompany Information MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications. Short Interest 173.05K 06/28/19 P/E Ratio (with extraordinary items) -150.46 Analyst Average Target: $11.00 Average Analyst Recommendation: BUY News: MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, will host an analyst day on its innovative product for chronic wounds on Monday, July 22nd at 12:00pm EDT in New York City. (Source: finance.yahoo.com)
NASDAQ:MDWDLong
by DEXWireNews
1
well-formed pennantYou can see that MDWD has moved up on higher volume recently from what appears to be the end of its down trend, and it is now in a clear pennant/ascending triangle. I did a search for "analyst opinion" on MediWound and it seems that the consensus is that it's a "strong buy". I don't understand why those experts say such things when the company is losing money, but it's losing less money and I have to figure that the pros understand these things better than me... nevertheless I'm still cautious. If there's going to be another move up then the triangle suggests it should be coming soon, and if it comes on another surge of volume I'll take a chance :-)
NASDAQ:MDWD
by germac